Cell/Gene Tx channel feed

Wal­greens will build out spe­cial­ty phar­ma­cy busi­ness, lean­ing in­to drug and ther­a­py ser­vices

Last year
Health Tech

Bio­Mar­in's Roc­ta­vian strug­gles con­tin­ue. Is a di­vest­ment in the fu­ture?

Last year
Pharma

Flag­ship’s gene edit­ing start­up Tessera cuts jobs as it shifts re­sources to clin­ic

Last year
People
Startups

Ex­clu­sive: Gene edit­ing start­up Seam­less hires ex-Ho­mol­o­gy leader, dou­bles seed round

Last year
People
Startups

Bris­tol My­ers, Cel­lares sign glob­al CAR-T deal as bio­phar­ma com­pa­nies look to di­ver­si­fy man­u­fac­tur­ing part­ners 

Last year
Deals
Manufacturing

J&J, Bris­tol My­ers race to am­pli­fy CAR-T man­u­fac­tur­ing to meet la­bel ex­pan­sion in mul­ti­ple myelo­ma

Last year
Manufacturing

Astel­las writes down an­oth­er piece of its Au­dentes gene ther­a­py ac­qui­si­tion

Last year
Pharma

En­livex’s shares cut in half af­ter ‘bi­as­es’ cloud Ph2 cell ther­a­py da­ta in sep­sis

Last year
R&D

CMS to in­crease re­im­burse­ment for new sick­le cell gene ther­a­pies

Last year
FDA+

FDA ap­proves J&J and Leg­end’s Carvyk­ti for sec­ond-line mul­ti­ple myelo­ma

Last year
Pharma
FDA+

‘Look be­fore you leap’: Cari­bou to start Ph1 au­toim­mune study of CAR-T ther­a­py

Last year
R&D

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Last year
R&D

Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Last year
Financing

Verve paus­es lead base edit­ing pro­gram af­ter safe­ty event, switch­es fo­cus to fol­low-up can­di­date near clin­ic

Last year
R&D

Caris­ma to lay off staff, drop clin­i­cal CAR-M pro­gram in fa­vor of sec­ond can­di­date

Last year
People
R&D

Of the few pre­clin­i­cal IPOs, Metageno­mi keeps de­tails about IND plans close

Last year
Startups

Brazil aims to man­u­fac­ture its own cell ther­a­pies — at a frac­tion of the cur­rent cost

Last year
Manufacturing

Nkar­ta drops a can­cer pro­gram, putting au­toim­mune front and cen­ter. Will it pay off?

Last year
R&D

Or­chard sets US price tag for rare dis­ease gene ther­a­py Len­meldy at $4.25M

Last year
Pharma

'Cell ther­a­py with­out cell­s': Cap­stan rais­es $175M to test in vi­vo CAR-T

Last year
Financing
Startups

FDA green­lights Or­chard's gene ther­a­py Len­meldy for rare and fa­tal dis­ease

Last year
Pharma
FDA+

Bris­tol My­ers scores ac­cel­er­at­ed ap­proval in more blood can­cers for CAR-T ther­a­py Breyanzi

Last year
Pharma
FDA+

UK's NICE says it's not ready to rec­om­mend Ver­tex's Cas­gevy for sick­le cell

Last year
Pharma

Swedish biotech rais­es €30M Se­ries A to de­vel­op off-the-shelf gene ther­a­py for sol­id tu­mors

Last year
Financing
Startups
First page Previous page 78910111213 Next page Last page
A service from the Financial Times